Within the Chronic Inflammatory Demyelinating Polyneuropathy Market segment, the treatment landscape is primarily categorized into Intravenous Immunoglobulin (IVIg), Corticosteroids, Immunosuppressive Therapy, and Plasmapheresis. IVIg currently represents the largest revenue-generating sub-segment due to its established efficacy as a first-line treatment and the need for frequent, high-dose...